CLLS — Cellectis S.A.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1627281 ·
France
Last close
$3.09
Market Cap
$224.37M
52W High
$4.55
52W Low
$2.89
ADV30
41,570
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,777,000 | 3,457,000 | -25,168,000 | -17,765,000 | 289,187,000 | 34,841,000 | 229,267,000 |
| Dec 2025 | 10,396,000 | 7,397,000 | -17,351,000 | -26,318,000 | 324,720,000 | 61,533,000 | 248,819,000 |
| Sep 2025 | 35,172,000 | 32,815,000 | 8,041,000 | 589,000 | 343,045,000 | 52,243,000 | 242,567,000 |
| Jun 2025 | 16,725,000 | 14,300,000 | -9,587,000 | -23,735,000 | 353,966,000 | 59,809,000 | 256,855,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,401,000
Investing CF
$-29,484,000
Financing CF
$-16,761,000
CapEx
$-3,533,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,131,000
Inventory
—
Receivables
$25,318,000
ST Investments
$147,130,000
EBIT TTM
$-59,909,000
Pretax Income TTM
$-68,016,000
Interest Exp TTM
$8,107,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$75,112,000
EBITDA
$-32,749,000
Free Cash Flow
$91,416,496
Enterprise Value
$121,250,776
Total Cash
$185,424,000
Total Debt
$82,335,000
Shares Out
72,611,481
Trailing EPS
$-0.67
Book Value
$0.82
ROE
-76.3%
ROA
-8.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,949,000 | -33,076,000 | -67,593,000 | 324,720,000 | 248,819,000 | — | -39,401,000 |
| Dec 2024 | 41,506,000 | -59,554,000 | -36,761,000 | 383,544,000 | 252,511,000 | — | 22,989,000 |
| Dec 2023 | 755,000 | -97,303,000 | -101,059,000 | 334,270,000 | 249,575,000 | — | -24,746,000 |
| Dec 2022 | 19,171,000 | -89,666,000 | -106,139,000 | 261,216,000 | 135,275,000 | — | -87,444,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.11 · call volume: 12 · put volume: 50
Expected Move to 2026-08-21:
±$2.60
(83.60%) —
implied range
$0.51 –
$5.71
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVVD | Invivyd, Inc. | $226.85M | $0.77 | — |
| IKT | Inhibikase Therapeutics, Inc. | $220.49M | $1.67 | — |
| TARA | Protara Therapeutics, Inc. | $219.20M | $3.90 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $231.68M | $2.50 | — |
| CHRS | Coherus Oncology, Inc. | $215.95M | $1.40 | — |
News headlines (Yahoo Finance, 1h cache)
Ferretti Leads The Charge In European Penny Stock Opportunities
2026-06-12 06:05 · Yahoo
Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients
2026-06-11 15:57 · Yahoo
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
2026-06-11 06:40 · Yahoo
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
2026-06-10 15:07 · Yahoo
CLLS Stock Rallies Over 24% After Hours — Here's Why
2026-06-09 22:30 · Yahoo
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
2026-06-09 20:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
2026-06-09 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
2026-06-08 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week
2026-06-05 15:06 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
2026-06-04 15:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.